ATOSSA THERAPEUTICS, INC. (ATOS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 250K 500K 750K Q2 '12: 279.3K Q3 '12: 384.9K Q4 '12: 481.8K Q1 '13: 609.8K Q2 '13: 712.8K Q3 '13: 683.8K Q4 '13: 632.6K Q1 '14: 474K Q2 '14: 157.8K Q3 '14: 84.6K Q4 '14: 40.1K Q1 '15: 16K Q2 '15: 6.1K Q3 '15: 2.7K Q4 '15: 1.8K Q1 '16: 1.8K Q2 '16: 1.8K Q3 '16: 1.8K Q4 '12 Q3 '13 Q2 '14 Q1 '15 Q4 '15 Q3 '16

Gross Profit TTM

-200K 0 200K 400K 600K Q2 '12: 137.3K Q3 '12: 227.8K Q4 '12: 416.2K Q1 '13: 504.7K Q2 '13: 403.3K Q3 '13: 363.5K Q4 '14: 40.1K Q1 '15: 16K Q2 '15: 6.1K Q3 '15: 461.6K Q4 '15: -130.7K Q1 '16: -130.7K Q2 '16: -130.7K Q2 '12 Q4 '12 Q2 '13 Q4 '14 Q2 '15 Q4 '15 Q2 '16

Operating Income TTM

-45M -30M -15M 0 15M 30M 45M Q3 '21: -19.9M Q4 '21: -20.5M Q1 '22: -21.7M Q2 '22: -21.3M Q3 '22: -24.4M Q4 '22: -27.7M Q1 '23: -30M Q2 '23: -31.2M Q3 '23: -30.5M Q4 '23: -31.4M Q1 '24: -31.3M Q2 '24: -30.6M Q3 '24: -29.5M Q4 '24: -27.6M Q1 '25: -28.1M Q2 '25: -30M Q3 '25: -32.9M Q4 '25: -37.1M Q1 '26: -39.6M Q2 '26: -39.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-45M -30M -15M 0 15M 30M 45M Q3 '21: -23.3M Q4 '21: -20.6M Q1 '22: -21.9M Q2 '22: -21.5M Q3 '22: -24.3M Q4 '22: -27M Q1 '23: -28.5M Q2 '23: -31.6M Q3 '23: -29.8M Q4 '23: -30.1M Q1 '24: -29.7M Q2 '24: -25.9M Q3 '24: -26.9M Q4 '24: -25.5M Q1 '25: -26.3M Q2 '25: -28.7M Q3 '25: -30.2M Q4 '25: -34.8M Q1 '26: -37.6M Q2 '26: -37.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 150K 300K 450K Q2 '12: 26.1K Q3 '12: 35.1K Q4 '12: 35.7K Q1 '13: 99K Q2 '13: 303.4K Q3 '13: 320.3K Q4 '13: 345.5K Q1 '14: 279.1K Q2 '14: 56.9K Q3 '14: 31K Q4 '14: 0 Q1 '15: 0 Q2 '15: 0 Q3 '15: 313.4K Q4 '15: 132.4K Q1 '16: 132.4K Q2 '16: 132.4K Q3 '12 Q2 '13 Q1 '14 Q4 '14 Q3 '15 Q2 '16

Operating Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q3 '21: -16.2M Q4 '21: -16.5M Q1 '22: -16.9M Q2 '22: -17.6M Q3 '22: -19.9M Q4 '22: -20.8M Q1 '23: -22.9M Q2 '23: -21.4M Q3 '23: -19.9M Q4 '23: -20.9M Q1 '24: -18.6M Q2 '24: -18.7M Q3 '24: -19.6M Q4 '24: -21M Q1 '25: -22.3M Q2 '25: -25M Q3 '25: -26.3M Q4 '25: -29.8M Q1 '26: -33.4M Q2 '26: -35.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q3 '21: -16.2M Q4 '21: -16.5M Q1 '22: -17M Q2 '22: -17.6M Q3 '22: -19.9M Q4 '22: -20.8M Q1 '23: -22.9M Q2 '23: -21.4M Q3 '23: -19.9M Q4 '23: -21M Q1 '24: -18.6M Q2 '24: -18.7M Q3 '24: -19.6M Q4 '24: -21M Q1 '25: -22.3M Q2 '25: -25M Q3 '25: -26.3M Q4 '25: -29.8M Q1 '26: -33.4M Q2 '26: -35.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '21: 92.6M Q2 '21: 121.6M Q3 '21: 126.5M Q1 '22: 126.6M Q2 '22: 126.6M Q3 '22: 126.6M Q1 '23: 126.6M Q2 '23: 126.6M Q3 '23: 125.8M Q1 '24: 125.3M Q2 '24: 125.7M Q3 '24: 125.8M Q1 '25: 8.6M Q2 '25: 8.6M Q3 '25: 129.2M Q1 '26: 8.6M Q2 '26: 8.9M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q3 '21: -1.02 Q4 '21: -0.18 Q1 '22: -0.18 Q2 '22: -0.17 Q3 '22: -0.19 Q4 '22: -0.21 Q1 '23: -0.22 Q2 '23: -0.25 Q3 '23: -0.24 Q4 '23: -0.24 Q1 '24: -0.24 Q2 '24: -0.21 Q3 '24: -0.22 Q4 '24: -3.05 Q1 '25: -3.78 Q2 '25: -4.71 Q3 '25: -4.72 Q4 '25: -5.69 Q1 '26: -6.02 Q2 '26: -5.99 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.